Compare Stocks: CASI, ADIL, QNRX, and CALC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$3.07 -6.7%	$4.94	$1.31 ▼ $10.19	$8.07M	1.5	197,380 shs	25,777 shs
CALC CalciMedica	$1.07 -4.9%	$2.27	$1.03 ▼ $36.00	$7.27M	0.76	184,787 shs	37,937 shs
CASI CASI Pharmaceuticals	$0.21	$0.21	$0.21 ▼ $3.09	$2.55M	0.91	482,532 shs	N/A
QNRX Quoin Pharmaceuticals	$4.14 -0.1%	$5.74	$3.25 ▼ $23.50	$8.33M	1.56	286,765 shs	155,033 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	-6.00%	-17.34%	-32.86%	+20.96%	-64.44%
CALC CalciMedica	-7.05%	-24.83%	-43.43%	-71.34%	-93.13%
CASI CASI Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-89.02%
QNRX Quoin Pharmaceuticals	-4.82%	-12.08%	-38.88%	-1.43%	-72.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$3.07 -6.7%	$4.94	$1.31 ▼ $10.19	$8.07M	1.5	197,380 shs	25,777 shs
CALC CalciMedica	$1.07 -4.9%	$2.27	$1.03 ▼ $36.00	$7.27M	0.76	184,787 shs	37,937 shs
CASI CASI Pharmaceuticals	$0.21	$0.21	$0.21 ▼ $3.09	$2.55M	0.91	482,532 shs	N/A
QNRX Quoin Pharmaceuticals	$4.14 -0.1%	$5.74	$3.25 ▼ $23.50	$8.33M	1.56	286,765 shs	155,033 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	-6.00%	-17.34%	-32.86%	+20.96%	-64.44%
CALC CalciMedica	-7.05%	-24.83%	-43.43%	-71.34%	-93.13%
CASI CASI Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-89.02%
QNRX Quoin Pharmaceuticals	-4.82%	-12.08%	-38.88%	-1.43%	-72.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	2.25	Hold	$8.33	169.34% Upside
CALC CalciMedica	2.20	Hold	$50.00	4,572.90% Upside
CASI CASI Pharmaceuticals	1.00	Sell	N/A	N/A
QNRX Quoin Pharmaceuticals	2.50	Moderate Buy	$17.00	316.16% Upside

Current Analyst Ratings Breakdown

Latest CASI, ADIL, QNRX, and CALC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	ADIL Adial Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/12/2026	QNRX Quoin Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$14.00
10/12/2026	QNRX Quoin Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$14.00
9/24/2026	ADIL Adial Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/23/2026	QNRX Quoin Pharmaceuticals	Lake Street Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$20.00
8/27/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	CALC CalciMedica	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy
8/13/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	CALC CalciMedica	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral
8/3/2026	ADIL Adial Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$11.00
7/29/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$4.75 per share	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	($2.30) per share	N/A
CASI CASI Pharmaceuticals	$26.85M	0.10	N/A	N/A	$0.12 per share	1.73
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	$15.64 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$7.98M	-$14.73	N/A	N/A	N/A	N/A	-203.87%	-512.41%	11/18/2026 (Estimated)
CALC CalciMedica	-$29.56M	-$6.80	N/A	N/A	N/A	N/A	N/A	-155.24%	11/11/2026 (Estimated)
CASI CASI Pharmaceuticals	-$39.26M	-$3.01	N/A	N/A	N/A	-183.93%	N/A	-131.54%	N/A
QNRX Quoin Pharmaceuticals	-$15.81M	-$25.18	N/A	N/A	N/A	N/A	-489.57%	-221.17%	11/5/2026 (Estimated)

Latest CASI, ADIL, QNRX, and CALC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	N/A	CALC CalciMedica	-$1.2750	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	QNRX Quoin Pharmaceuticals	-$1.88	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	ADIL Adial Pharmaceuticals	-$1.0325	-$11.25	-$10.2175	-$11.25	N/A	N/A
8/14/2026	Q2 2026	QNRX Quoin Pharmaceuticals	-$1.61	-$1.90	-$0.29	-$1.90	N/A	N/A
8/11/2026	Q2 2026	CALC CalciMedica	-$1.4250	-$0.45	+$0.9750	-$2.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	5.63	5.63
CALC CalciMedica	1.67	5.58	5.58
CASI CASI Pharmaceuticals	N/A	0.30	0.24
QNRX Quoin Pharmaceuticals	N/A	1.76	1.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
CALC CalciMedica	N/A
CASI CASI Pharmaceuticals	22.23%
QNRX Quoin Pharmaceuticals	8.63%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	8.00%
CALC CalciMedica	28.25%
CASI CASI Pharmaceuticals	21.24%
QNRX Quoin Pharmaceuticals	7.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	6	2.63 million	2.42 million	No Data
CALC CalciMedica	15	6.83 million	4.90 million	No Data
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
QNRX Quoin Pharmaceuticals	6	2.01 million	1.86 million	Not Optionable

CASI, ADIL, QNRX, and CALC Headlines

Recent News About These Companies

Quoin Secures EMA Orphan Drug Designation For QRX003 In Rare Skin Disorder

2 hours ago | rttnews.com

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

October 14 at 6:30 AM | globenewswire.com

BTIG Research Begins Coverage on Quoin Pharmaceuticals (NASDAQ:QNRX)

October 13 at 6:02 AM | americanbankingnews.com

Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy

October 6, 2026 | globenewswire.com

Four Small-Cap Stocks to Watch With Small Floats and Big Catalysts (CHGA, QNRX, MYSE, LNKS)

September 25, 2026 | marketscreener.comM

Quoin Gets FDA Fast Track Designation For QRX003 In Peeling Skin Syndrome

September 23, 2026 | rttnews.com

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

September 22, 2026 | finanznachrichten.de

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

September 22, 2026 | globenewswire.com

Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

September 10, 2026 | finance.yahoo.com

Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

September 10, 2026 | globenewswire.com

FDA Grants Rare Pediatric Disease Designation To Quoin's QRX003 For PSS

September 8, 2026 | rttnews.com

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

September 8, 2026 | globenewswire.com

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

September 8, 2026 | globenewswire.com

Insider Buying: Quoin Pharmaceuticals (NASDAQ:QNRX) Director Acquires $29,992.48 in Stock

September 2, 2026 | insidertrades.com

Quoin Pharma raises up to $50M for rare disease development

August 29, 2026 | thepharmaletter.comT

Quoin Pharma Surges 45% In Pre-Market On Positive QRX003 Data And $50M Private Placement

August 28, 2026 | rttnews.com

Quoin Pharmaceuticals stock surges Friday: What's happening?

August 28, 2026 | msn.com

Quoin Pharma Reports Positive Interim Data From Ongoing Phase 2/3 Study Of QRX003

August 28, 2026 | rttnews.com

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million

August 28, 2026 | globenewswire.com

Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome

August 28, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CASI, ADIL, QNRX, and CALC Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$3.07 -0.22 (-6.69%)

As of 04:00 PM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

CalciMedica NASDAQ:CALC

$1.06 -0.06 (-4.91%)

Closing price 03:59 PM Eastern

Extended Trading

$1.06 0.00 (0.00%)

As of 04:04 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

CASI Pharmaceuticals NASDAQ:CASI

$0.21 0.00 (0.00%)

As of 10/13/2026

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Quoin Pharmaceuticals NASDAQ:QNRX

$4.14 -0.01 (-0.14%)

Closing price 03:59 PM Eastern

Extended Trading

$4.12 -0.03 (-0.60%)

As of 04:02 PM Eastern

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CASI, ADIL, QNRX, and CALC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CASI, ADIL, QNRX, and CALC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CASI, ADIL, QNRX, and CALC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CASI, ADIL, QNRX, and CALC Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

CalciMedica NASDAQ:CALC

CASI Pharmaceuticals NASDAQ:CASI

Quoin Pharmaceuticals NASDAQ:QNRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CASI, ADIL, QNRX, and CALC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CASI, ADIL, QNRX, and CALC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CASI, ADIL, QNRX, and CALC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CASI, ADIL, QNRX, and CALC Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

CalciMedica NASDAQ:CALC

CASI Pharmaceuticals NASDAQ:CASI

Quoin Pharmaceuticals NASDAQ:QNRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools